RN1201 injection for blood cancers that have come back or not responded
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy, Infections clinical trials.
This trial tests a new treatment called RN1201 for blood cancers like multiple myeloma, certain leukemias, and lymphomas that have not improved with standard treatments or have returned. The treatment targets specific markers on cancer cells (CD19 and BCMA) and may offer a new option for patients who have run out of standard choices.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a blood cancer (like multiple myeloma, B-cell acute lymphoblastic leukemia, or certain lymphomas) that is CD19-positive or BCMA-positive.
- Your cancer has not responded to standard treatment or has returned after an initial response.
- You must have measurable signs of cancer, such as a tumor that is at least 1.5 cm, or in some cases, detectable cancer cells even if scans look clear.
- You are at least 18 years old.
- Your overall health is reasonably good (doctors will check your heart, kidneys, liver, and blood counts).
- You are not pregnant or breastfeeding, and you agree to avoid pregnancy for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new injection called RN1201 for people with antibody-mediated diseases, specifically two types of blood disorders: platelet transfusion refractoriness (PTR) and immune thrombocytopenia (ITP) that haven't responded to standard treatments. The goal is to see if RN1201 can help control these conditions.
This study tests an investigational injection called RN1201 for people whose autoimmune disease (like lupus, myasthenia gravis, or immune thrombocytopenia) has not responded to standard therapies. The goal is to see if it can better control the disease.
This trial tests a new drug called RN1201 as a first-line treatment for multiple myeloma, a blood cancer. The study aims to see if it is safe and effective for patients who have never been treated for this condition before.
This trial tests a new treatment using specially engineered immune cells from a healthy donor to fight certain B-cell blood cancers that have come back or not responded to standard therapy. It aims to see if these cells can safely help patients achieve remission.
This study tests an investigational drug called RN1701 for people with certain types of B-cell lymphoma that have not responded to or have returned after previous treatments. The goal is to see if the drug can help control the cancer.
This trial tests a new treatment using specially modified immune cells (CAR-T cells) to fight certain blood cancers that have come back or haven't improved with standard treatments. It may help your body's own immune system attack the cancer cells.
Hear when a new Plasmablastic Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.